Literature DB >> 1747227

Prognostic variables in parotid gland cancer.

R A Frankenthaler1, M A Luna, S S Lee, K K Ang, R M Byers, O M Guillamondegui, P Wolf, H Goepfert.   

Abstract

We performed a retrospective review of 178 previously untreated patients with primary malignant neoplasms of the parotid gland treated at our institution between 1960 and 1985. Patients were followed up for a median of 7.5 years. Fifty-nine percent underwent surgery alone, and 40% underwent surgery and radiation therapy. Univariate and multivariate analyses established the prognostic influence of cancer stage, cancer grade, histologic type, presence of lymphatic invasion, perineural invasion, tumor size, extension beyond the parotid gland fascia, cervical adenopathy, quality of margins, and patient age and gender. Survival was influenced most by tumor grade, tumor size, presence of positive cervical lymph nodes, and facial nerve invasion. The risk of local-regional recurrence was most affected by cervical adenopathy and tumor size. Distant metastases were predicted by tumor grade and size. At last contact, 39% of patients were alive and free of disease, while 26% had died of the disease. We analyzed the optimal surgical procedure and the rationale for the selection of combined treatment.

Entities:  

Mesh:

Year:  1991        PMID: 1747227     DOI: 10.1001/archotol.1991.01870230067009

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  21 in total

1.  Outcomes of temporal bone resection for locally advanced parotid cancer.

Authors:  Saral Mehra; Luc G Morris; Jatin Shah; Mark Bilsky; Samuel Selesnick; Dennis H Kraus
Journal:  Skull Base       Date:  2011-11

2.  Histological characteristics of intra-temporal facial nerve paralysis in temporal bone malignancies.

Authors:  Omer J Ungar; Joseph B Nadol; William C Faquin; John P Carey; Ophir Handzel; Felipe Santos
Journal:  Laryngoscope       Date:  2019-08-01       Impact factor: 3.325

3.  Results of surgery plus postoperative radiotherapy for patients with malignant parotid tumor.

Authors:  Shogo Matsuda; Hiroyoshi Iguchi; Takuhito Tada; Masako Hosono; Masahiko Osawa; Yuuko Kuwae; Hideyuki Morimoto; Eiichiro Okazaki; Kosuke Amano; Yoshitaka Miki; Shinichi Tsutsumi; Yasuhiko Shimatani; Yukio Miki
Journal:  Jpn J Radiol       Date:  2015-07-10       Impact factor: 2.374

4.  Role of fine needle aspiration cytology in the management of the discrete parotid lump.

Authors:  M McGurk
Journal:  Ann R Coll Surg Engl       Date:  1998-01       Impact factor: 1.891

5.  Preoperative diagnostic of parotid gland neoplasms: fine-needle aspiration cytology or core needle biopsy?

Authors:  Peter Zbären; Asterios Triantafyllou; Kenneth O Devaney; Vincent Vander Poorten; Henrik Hellquist; Alessandra Rinaldo; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-09-20       Impact factor: 2.503

Review 6.  [Salivary gland carcinomas. 1. Epidemiology, etiology, malignancy criteria, prognostic parameters and classification].

Authors:  S Lang; N Rotter; A Lorenzen; S Ihrler; R Eckel; D Hölzel; G Rasp; B Wollenberg; K Sommer
Journal:  HNO       Date:  2005-09       Impact factor: 1.284

7.  Kaplan-Meier analysis of salivary gland tumors: prognosis and long-term survival.

Authors:  Yair Israel; Adi Rachmiel; Konstantin Gourevich; Rafael Nagler
Journal:  J Cancer Res Clin Oncol       Date:  2019-06-11       Impact factor: 4.553

8.  An audit of surgery of the parotid gland.

Authors:  G T Deans; K Briggs; R A Spence
Journal:  Ann R Coll Surg Engl       Date:  1995-05       Impact factor: 1.891

9.  Treatment Results of Major Salivary Gland Cancer by Surgery with or without Postoperative Radiation Therapy.

Authors:  Jae Myoung Noh; Yong Chan Ahn; Heerim Nam; Won Park; Chung-Hwan Baek; Young-Ik Son; Han-Sin Jeong
Journal:  Clin Exp Otorhinolaryngol       Date:  2010-06-30       Impact factor: 3.372

Review 10.  Cancer of the parotid gland: role of 7th nerve preservation.

Authors:  Jeffrey D Spiro; Ronald H Spiro
Journal:  World J Surg       Date:  2003-07       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.